Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for human bypass grafts.

A A Mangi, V J Dzau

    Annals of Medicine
    |May 24, 2001
    PubMed
    Summary

    Autologous vein grafts for arterial bypass often fail. The PREVENT trial used E2F decoy oligonucleotide transfection to reduce cell proliferation, significantly lowering graft failure in peripheral arterial disease patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cell-cycle regulation of sarcomere integrity-Role for Actn2 phosphorylation.

    Physiological reports·2026
    Same author

    Gene therapy: role in myocardial protection.

    Handbook of experimental pharmacology·2006
    Same author

    Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival.

    Gene therapy·2004
    Same author

    Focused ultrasound (HIFU) induces localized enhancement of reporter gene expression in rabbit carotid artery.

    Gene therapy·2003
    Same author

    Apolipoprotein E-deficient mice created by systemic administration of antisense oligodeoxynucleotides: a new model for lipoprotein metabolism studies.

    The Journal of endocrinology·2002
    Same author

    Physiological Genomics: Who we are and where we're going.

    Physiological genomics·2002

    Area of Science:

    • Vascular Surgery
    • Molecular Biology
    • Gene Therapy

    Background:

    • Autologous saphenous vein grafts are standard for arterial bypass but suffer high failure rates.
    • Peripheral arterial disease (PAD) and coronary artery bypass grafting (CABG) show 20% and 50% 10-year graft failure, respectively.
    • Graft failure is linked to smooth muscle cell proliferation within the vein graft.

    Purpose of the Study:

    • To evaluate the efficacy of ex vivo E2F decoy oligonucleotide transfection in reducing vein graft failure.
    • To assess the impact of this gene therapy on smooth muscle cell proliferation markers.
    • To determine the clinical benefit in high-risk patients undergoing peripheral arterial bypass.

    Main Methods:

    • Harvested saphenous vein grafts were transfected ex vivo with an E2F decoy oligonucleotide.
    • Proliferating cell nuclear antigen (PCNA) and c-myc mRNA levels were quantified in smooth muscle cells.
    • The PREVENT trial assessed clinical outcomes in patients receiving treated grafts for peripheral arterial occlusions.

    Main Results:

    • Transfection resulted in a 70-74% decrease in PCNA and c-myc mRNA levels.
    • This reduction in smooth muscle cell proliferation was statistically significant.
    • A significant reduction in primary graft failure was observed in the treated high-risk patient group.

    Conclusions:

    • Ex vivo E2F decoy oligonucleotide transfection is a safe and effective method to improve vein graft patency.
    • Targeting smooth muscle cell proliferation is a promising strategy to reduce graft failure in arterial bypass.
    • This gene-mediated approach offers a novel therapeutic option for patients with peripheral arterial disease.

    Related Experiment Videos